Dryden Gold Corp. announced the discovery of visible gold in its first drill program at Mud Lake North, near Gold Rock, following high-grade surface samples from 2025. The initial three drill holes showed broad alteration zones with sulphide mineralization, and visible gold was found in the third hole. This discovery supports the company's theory of multiple gold deposits along the Manitou-Dinorwic deformation zone and strengthens confidence in further finds across the Gold Rock Camp. Drilling continues with about 2,000 meters planned to explore down-plunge and along strike, with assay results pending.
Dryden Gold's discovery of visible gold at Mud Lake North is presented here with Pluang's market data as of Sep 17, 2026 17:02 WIB: out of 150 priced US stocks tradable on Pluang, 133 rose and 13 fell today. Notable movers include NOK at USD 10.73 with a 1-day change of +5.82%, MRNA at USD 150.74 with +3.52%, and AFRM at USD 74.09 with +3.51%. The most notable figure is the breadth of 133 rising stocks.
Broadcom, JPMorgan Chase, and Coca-Cola have each delivered substantial long-term returns through durable earnings and dividends. Broadcom benefits from booming AI semiconductor demand, projecting $230 billion revenue in fiscal 2028. JPMorgan Chase c...
Costco has partnered with DoorDash to offer same-day delivery across the United States, allowing members to order groceries, household essentials, electronics, and more from local Costco warehouses through the DoorDash app. This expands their existin...
Netflix Chief Content Officer Bela Bajaria revealed the company's strategy to focus on "unmissable" live sports events, including a potential package of international NFL games if available during future media rights negotiations. Netflix currently h...
Group Eleven Resources announced that re-analysis of drill samples from its Ballywire discovery in Ireland using a new sodium peroxide fusion assay method showed germanium grades 68% higher on average than previous tests. Germanium, a valuable semico...
OS Therapies has reached agreement with the FDA, MHRA, and EMA on an adaptive design for its Phase 3 trial of OST-HER2, a gene-edited cancer immunotherapy targeting metastatic osteosarcoma. The company will start this trial in late 2026 and plans a k...
